Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation

NCT03666559 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Recurrent IDH1/2 Mutated Glioma

Interventions

DRUG: Azacitidine

Sponsor

Assistance Publique - Hôpitaux de Paris